2 completed, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow INE963: new trials by email Literature Review of INE963 trials Research Report on INE963
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1) KAE609 (Cipargamin), SoC (Coartem), INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 95 | 2025-10-10 | 2026-09-10 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria INE963 - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Completed | Novartis Pharmaceuticals | 52 | 2024-01-23 | 2025-11-19 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria INE963, KAE609 (Cipargamin), SoC (Coartem) - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Recruiting | Novartis Pharmaceuticals | 327 | 2024-01-23 | 2025-07-30 |
Malaria, Falciparum (3) · Malaria (1)
Burkina Faso (3) · Côte d’Ivoire (3) · Gabon (3) · Ghana (3) · Kenya (3) · Uganda (3) · Rwanda (1)